Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maes, B. D.
Right arrow Articles by Vanrenterghem, Y. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maes, B. D.
Right arrow Articles by Vanrenterghem, Y. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1999) 14: 2824-2826
© 1999 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation

Bart D. Maes and Yves F. Vanrenterghem

Department of Nephrology, University Hospital Gasthuisberg, Leuven, Belgium

Correspondence and offprint requests to: Yves Vanrenterghem, Department of Nephrology, University Hospital Gasthuisberg, B-3000 Leuven, Belgium.E-mail: Yves.Vanrenterghem@UZ.K U Leuven.ac.be.

Introduction

Although life-long administration of a multi-drug regimen of aspecific small-molecular immunosuppressants is most frequently used to prevent rejection of the transplanted organ, the administration of anti-T cell antibodies in the immediate post-transplant period (induction therapy) as prophylaxis against rejection or as anti-rejection therapy is still advocated to improve long-term allograft outcome. However, older polyclonal (ALS–ATG) and monoclonal (OKT3) anti-T cell antibodies are associated with different side-effects: (i) the development of anti-xenogeneic antibodies is associated with decreased immunosuppressive effects, serum sickness and anaphylactic reactions with repeated administration, (ii) cross-reactions with non-T cell tissue (e.g. thrombopenia, leukopenia), (iii) morbidity due to target cell activating antigen-specific reactions (cytokine release syndrome), and (iv) aspecific over-immunosuppression (e.g. CMV-infection, post-transplant lymphoproliferative disorder (PTLD)) due to interference with cells not involved in the rejection process or induction of microbial proliferation by substances released from anti-T cell antibody activated cells. Recently monoclonal antibodies (mAb) directed against the . . . [Full Text of this Article]

The IL-2/IL-2 receptor pathway

Development of IL-2R{alpha} monoclonal antibodies

Clinical studies with IL-2R{alpha} monoclonal antibodies

IL-2R{alpha} monoclonal antibodies: future prospects

Conclusion

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GutHome page
G Van Assche, W J Sandborn, B G Feagan, B A Salzberg, D Silvers, P S Monroe, W M Pandak, F H Anderson, J F Valentine, G E Wild, et al.
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
Gut, November 1, 2006; 55(11): 1568 - 1574.
[Abstract] [Full Text] [PDF]